Kadiyala N, Hovorka R, Boughton CK
Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R (2017) Targeting the gut-liver axis in liver disease
In 2 retrospective studies of ketamine for the treatment of refractory headache, which included individuals with chronic migraine, continuous subanesthetic doses of intravenous ketamine reduced headache severity acutely when dosed from 0.1 mg/kg/h to a maximum of 1 mg/kg/h titration based on drug tolerability
, A Rationally Designed Monomeric Peptide Triagonist Corrects Obesity and Diabetes in Rodents, Nature Medicine 21, no
Its emergence marks a move toward multi-pathway targeted weight management treatments
It was estimated that patients return to baseline weight within 1.7 years for any weight-management medication, 1.6 years for incretin mimetics, and 1.5 years for semaglutide and tirzepatide